TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21397567
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (44 μg subcutaneously three times per week)
Study: 18347652
Drug: Protein-enriched recovery
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-enriched recovery (0.7 g.kg(‐1).h(‐1) protein)
Study: 18347652
Drug: Control recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control recovery (0.1 g.kg(‐1).h(‐1) protein)
Study: 14728824
Drug: Anticoagulants therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants therapy
Study: 10678121
Drug: Huperzine-A capsules
Normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine-A capsules (Hup) 50 micrograms, 2 capsules b.i.d. for 4 weeks
Study: 10678121
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch and lactose), 2 capsules b.i.d. for 4 weeks
Study: 10678121
Drug: Huperzine-A capsules
Normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine-A capsules (Hup)
Study: 1875406
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (n = 25)
Study: 6342360
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support therapy group
Study: 28150856
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) in addition to pulmonary rehabilitation
Study: 26714460
Drug: Lifestyle physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle physical activity - participants receive a resource pack and pedometer, aiming to increase daily steps to 10,000 steps/day.
Study: 23988418
Drug: DBGT (double-brewed
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBGT (double-brewed green tea), 500 mL daily until recurrence or during a follow-up of 18 months
Study: 31740428
Drug: GKT137831 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GKT137831 400 mg BID for 48 weeks
Study: 23765950
Drug: Severe eosinophilia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe eosinophilia (≥ 1.0 × 10(9) /L)
Study: 23765950
Drug: Mild eosinophilia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild eosinophilia (≥ 0.5‐1.0 × 10(9) /L)
Study: 9066005
Drug: Bradykinin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin infusion
Study: 8872666
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside infusion
Study: 14733451
Drug: Intramuscular olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular olanzapine (10.0 mg)
Study: 10883158
Drug: Daily i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily i.v. glucosamine sulfate (GS) together with 800 mg chondroitin sulfate for 4 weeks
Study: 8255520
Drug: Ganciclovir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (5 mg/kg b.i.d./day for 14 days)
Study: 3987531
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg, retard form)
Study: 1995258
Drug: Verapamil (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (160 mg)
Study: 22959318
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose in normal saline solution
Study: 9360566
Drug: Premixed slurry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premixed slurry of deferoxamine mesylate (DFO) and activated charcoal (AC) with 5 mg/kg ferrous sulfate and 8 g of DFO and 25 g of 20% AC
Study: 9360566
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg ferrous sulfate alone
Study: 9360566
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg ferrous sulfate added to 25 g of 20% AC
Study: 1492440
Drug: Conventional or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional or no antiarrhythmic therapy
Study: 24513787
Drug: Interleukin‐2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin‐2 receptor antagonists (daclizumab or basiliximab)
Study: 23056520
Drug: Acidform gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidform gel
Study: 23056520
Drug: HEC placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC placebo gel
Study: 1927911
Drug: nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nisoldipine 10 mg once daily
Study: 1927911
Drug: nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nisoldipine 10 mg twice daily
Study: 1927911
Drug: nisoldipine 20
Normalized name: nisoldipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nisoldipine 20 mg once daily
Study: 29251433
Drug: Not feeling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not feeling ready to seek treatment
Study: 23343932
Drug: Pentavalent bovine‐human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent bovine‐human reassortant rotavirus vaccine
Study: 19101754
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral 1 mg minodronate for 24 months
Study: 15258682
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg bid
Study: 15258682
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg bid
Study: 11528141
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg twice a day, adjusted weekly until a minimum decrease of 20% in cardiac frequency achieved)
Study: 9401836
Drug: Ketamine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2.5, 3.5, or 6.0 mg/kg) via jet injector
Study: 9401836
Drug: Ketamine (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (dosage based on mg/m2 body surface area or mg/kg body weight)
Study: 8438810
Drug: DT-aP vaccine
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DT-aP vaccine
Study: 8438810
Drug: WC-DTP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC-DTP vaccine
Study: 2979214
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.m. for 14 days
Study: 22717925
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (Cypher; Cordis, Miami Lakes, FL, USA; n=20 patients)
Study: 20130836
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg morphine in 20 ml saline
Study: 20130836
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.25% bupivacaine
Study: 20130836
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml saline (placebo)
Study: 18759644
Drug: Aripiprazole (APZ)
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole (APZ) at a mean dose of 6.7 mg/day
Study: 12679354
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 6 mg/day
Study: 12679354
Drug: discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: discontinuation of rhGH therapy
Study: 8960947
Drug: Fish oils
Normalized name: fish oils
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oils (12 capsules, 3.6 g/day of omega 3)
Study: 8960947
Drug: Soya oil
Normalized name: Soya oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya oil (12 capsules per day)
Study: 6622502
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg theophylline tablet taken as 2 halves
Study: 6622502
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg theophylline tablet taken whole
Study: 31831255
Drug: B-cell activating
Normalized name: B-cell activating factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-cell activating factor receptor (Ianalumab) inhibition
Study: 31831255
Drug: Lymphotoxin beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphotoxin beta receptor (baminercept)
Study: 31831255
Drug: Other kinase
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other kinase inhibitors
Study: 31831255
Drug: Transmembrane activator
Normalized name: Human Transmembrane Activator and CAML Interactor (TACI) Immunoglobulin G1 Fc Domain Fusion Protein (Fc5)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmembrane activator and calcium-modulator and cytophilin ligand interactor TACI fusion protein (RC18)
Study: 31831255
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose recombinant interleukin-2 to expand T-regulatory cells
Study: 30870970
Drug: Watermelon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon (2 cups daily)
Study: 12174061
Drug: Graftskin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graftskin therapy with aggressive debridement and standardized wound care
Study: 9714263
Drug: Venlafaxine, 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine, 37.5 mg twice daily (increased to 75 mg twice daily after 3 weeks if poor response)
Study: 9714263
Drug: Fluoxetine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, 20 mg once daily (increased to 20 mg twice daily after 3 weeks if poor response)
Study: 2617209
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of amoxycillin
Study: 2617209
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of amoxycillin combined with 1 g of probenecid
Study: 28670249
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program based on the Precede model, conducted during four sessions twice a week for one hour.
Study: 21768737
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (SP) formula containing 12 g of SP, given for 20 weeks
Study: 19537839
Drug: Lubiprostone 8
Normalized name: LUBIPROSTONE 8MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 8 microg twice daily for 3 months
Study: 19537839
Drug: Lubiprostone 8
Normalized name: LUBIPROSTONE 8MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 8 microg twice daily
Study: 16414215
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day isoflavone supplement (n=15)
Study: 16414215
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo capsules (n=14)
Study: 8808491
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ascorbate per day for 4 weeks
Study: 1393763
Drug: Azelastine, 0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine, 0.28 mg to each nostril
Study: 25412225
Drug: IV antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV antibiotics
Study: 31373271
Drug: PO antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO antibiotics
Study: 12131220
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine (one or two doses)
Study: 12131220
Drug: Polysaccharide vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide vaccine (one dose)
Study: 12131220
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pneumococcal conjugate and polysaccharide vaccines (one dose of each)
Study: 9607049
Drug: Injection in
Normalized name: Emend Injection Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection in the buttock
Study: 9607049
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of OPV and/or HBV
Study: 7618425
Drug: i.v. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketorolac tromethamine 30 mg
Study: 2151275
Drug: Zoladex plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex plus flutamide (Zoladex 3.6 mg every 4 weeks, flutamide 250 mg t.i.d.)
Study: 23340533
Drug: Quinidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (50 mg)
Study: 19059635
Drug: Whole-body hyperthermia
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body hyperthermia (WBH) in combination with carboplatin
Study: 16919060
Drug: Intensive advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive advice to withdraw the overused medication (Group A)
Study: 16919060
Drug: Standard out‐patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard out‐patient detoxification programme (advice+prednisone+preventive treatment) (Group B)
Study: 11164700
Drug: Rufinamide (400-1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufinamide (400-1600 mg/day)
Study: 9245470
Drug: Compound cue
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound cue model
Study: 2826550
Drug: IV enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV enalaprilat 1.25 mg q6h for 24 hours, increased to 5 mg q6h for nonresponding patients
Study: 29562147
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy with antibiotics
Study: 25403867
Drug: Chia flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chia flour (35 g/day) for 12 weeks
Study: 11934185
Drug: 1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 percent penciclovir cream
Study: 10860034
Drug: Tetracycline fiber
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline fiber therapy
Study: 1973351
Drug: Social Skills
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Skills Training (SST) - 25 twice a week 90-min group sessions
Study: 1973351
Drug: Group Exposure
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Exposure (GE) - 4 weekly sessions (8-hr total, including 2 hr discussion)
Study: 1973351
Drug: Individual Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Exposure (IE) - 4 weekly sessions (3 hr total, including 1 hr discussion)
Study: 504040
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid 250 mg
Study: 28812321
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily (Group B)
Study: 28812321
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily (Group A)
Study: 26596056
Drug: Dabigatran (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (110 mg b.i.d)
Study: 26596056
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg b.i.d)
Study: 19747876
Drug: Dexamethasone-based protocol
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone-based protocol (DCOG ALL-9) for NHR patients: three-drug induction (dexamethasone, vincristine, asparaginase) for 6 weeks, medium-dose methotrexate for 3 weeks, maintenance therapy until 109 weeks.
Study: 19747876
Drug: Dexamethasone-based protocol
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone-based protocol (DCOG ALL-9) for HR patients: four-drug induction (as for NHR plus daunorubicin) for 6 weeks, high-dose methotrexate for 8 weeks, maintenance therapy until 109 weeks.
Study: 11455770
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms PGE1 + 15 mg papaverine hydrochloride + 0.5 mg phentolamine (trimix)
Study: 11455770
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg papaverine hydrochloride + 1 mg phentolamine (bimix)
Study: 28526536
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine (3·6 mg/kg intravenously every 3 weeks)
Study: 28526536
Drug: Capecitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1000 mg/m2 orally twice daily on days 1‐14 of each 21-day cycle) plus Lapatinib (1250 mg orally once daily on days 1‐21)
Study: 12940872
Drug: Sibutramine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine, 10 mg once daily
Study: 11885173
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in the study
Study: 11885173
Drug: Stratified analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified analysis of data up to 72 months after implant uncovering
Study: 8833025
Drug: Theoretically based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theoretically based, structured experimental treatment program
Study: 1467099
Drug: Alfentanil loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil loading dose of 85 micrograms kg‐1 and infusion of 65 micrograms kg‐1 h‐1
Study: 1467099
Drug: Alfentanil loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil loading dose of 65 micrograms kg‐1 and infusion of 50 micrograms kg‐1 h‐1
Study: 6205337
Drug: Cis-dichlorodiammineplatinum(II) (cis-DDP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-dichlorodiammineplatinum(II) (cis-DDP) 33 mg/kg i.v. day 1 and Bleomycin (BLM) 15 mg/m2 i.v. continuously day 2-6 (arm A)
Study: 6205337
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 30 mg/m2 i.v. day 1 + 6 and Vindesine (VDS) 3 mg/m2 day 2 + 7 (arm B)
Study: 6205337
Drug: Chemotherapy (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (both arms combined)
Study: 29659797
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg b.i.d., reduced to 2.5 mg b.i.d. if applicable)
Study: 29659797
Drug: Heparin/Vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/Vitamin K Antagonist (VKA)
Study: 15643230
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg Serenoa repens (SR) orally twice daily for 3 months
Study: 15643230
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 3 weeks before surgery)
Study: 9272316
Drug: Ciprofloxacin ophthalmic
Normalized name: ciprofloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin ophthalmic solution (0.3%)
Study: 8997576
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid gel (1%)
Study: 1360665
Drug: recombinant gp160
Normalized name: Recombinant gp160 vaccine
DrugBank: VaxSyn (DB17827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant gp160 vaccine
Study: 1360665
Drug: recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant hepatitis B vaccine (control)
Study: 6142907
Drug: Alprazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (2 to 6 mg/day)
Study: 6142907
Drug: Ibuprofen (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (0.8 to 2.4 g/day)
Study: 6142907
Drug: Alprazolam (6.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (6.3 mg/day after crossover)
Study: 29480087
Drug: Running and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running and brisk walking for 30‐45 min twice a week (IND)
Study: 29480087
Drug: Running and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running and brisk walking for 30‐45 min twice a week (GR)
Study: 25560349
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel dressing
Study: 23103771
Drug: Internet-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based therapy (IT)
Study: 16166192
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 500-3000 mg/day
Study: 17644828
Drug: Benzodiazepine discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine discontinuation programme with group psychotherapy
Study: 17644828
Drug: Benzodiazepine discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine discontinuation programme without psychotherapy
Study: 17644828
Drug: Complete discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete discontinuation of benzodiazepines
Study: 15859929
Drug: BT563 (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT563 (monoclonal antibody against interleukin-2 receptor) for 10 days in kidney transplant recipients
Study: 15859929
Drug: BT563 (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT563 (monoclonal antibody against interleukin-2 receptor) for 7 days in heart transplant recipients